Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARBICAN neoadjuvant ipatasertib + atezolizumab in triple-negative breast cancer
2018-000977-62Phase 2Unknown
- Sponsor
- Queen Mary University of London
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipatasertib in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Queen Mary University of London. Primary endpoints: Pathological complete response (pCR) in breast and axilla (overall population) and Pathological complete response (pCR) by PIK3CA/AKT1/PTEN alteration status. Status: unknown.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2018-000977-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000977-62.